Tag
This qualitative study reveals empowerment as central to promoting safer mobility in Parkinson’s disease, emphasizing individualized, contextual, and collaborative strategies for fall prevention.
This study links higher physical activity levels with slower cognitive and motor decline in Parkinson’s disease, highlighting the importance of sustained activity engagement.
Analysis of two large cohorts reveals no significant association between levodopa use and freezing of gait in Parkinson’s disease after adjusting for disease severity and duration, emphasizing the primary role of disease progression in this
This review explores evidence linking smoking and exhaled carbon monoxide levels to reduced Parkinson’s disease risk, emphasizing a potential protective role of carbon monoxide, supported by recent large-scale cohort data and biologic
This study links MC1R loss-of-function variants to faster motor decline and phenoconversion in Parkinson’s disease, suggesting their value for prognosis and clinical trial design in European descent patients.
The phase 3 TEMPO-2 trial demonstrates that flexible-dose tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improves motor symptoms in early Parkinson’s disease with a manageable safety profile, warranting further
This review synthesizes evidence from a large-scale multi-ancestry study revealing ancestry-specific distributions of Parkinson’s disease genetic variants, emphasizing the need for diverse population inclusion to optimize diagnosis an
This review synthesizes evidence on staged, bilateral MRgFUS pallidothalamic tractotomy for Parkinson’s motor complications, highlighting demonstrated unilateral safety and modest bilateral efficacy with increased adverse events, unde
The Phase 3 TEMPO-3 trial demonstrates that tavapadon, a selective D1/D5 agonist, significantly increases ‘good-on-time’ and reduces ‘off-time’ in Parkinson’s patients with motor fluctuations, offering a favorable sa
A groundbreaking clinical trial reveals that adaptive deep brain stimulation (aDBS) provides a safer, more efficient, and personalized way to manage Parkinson’s disease symptoms by responding to real-time brain activity.
This review synthesizes recent large-scale genomic evidence (ROPAD, PD GENEration, MDSGene) to outline the diagnostic yield, ethnic variations, and genotype-phenotype correlations in Parkinson’s disease, emphasizing the transition toward un
A large-scale longitudinal study reveals that α-synuclein seed amplification assay (SAA) kinetic measures, particularly time to threshold, can differentiate Parkinson’s from PSP and predict future cognitive decline independently of Al
The AZA-PD phase 2 trial found that while azathioprine was well-tolerated in early Parkinson’s disease, it did not significantly improve gait-axial scores. However, exploratory data suggests potential motor benefits in female patients
A 20‑year TriNetX analysis of 913,428 T2DM patients found SGLT2 inhibitor use associated with a 28% lower Parkinson’s disease risk versus metformin (aHR 0.72), suggesting possible superior neuroprotection and prompting need for prospective
The APOE ε4 allele significantly reduces survival in Parkinson’s disease patients independently of dementia, linked to mitochondrial dysfunction and ER stress in PD models.
This study reveals how virulence factors in oral and gut microbiomes and their translocation affect cognitive impairment in Parkinson’s disease, highlighting novel biomarker potential and the importance of the oral-gut-brain axis for early
Intensive treadmill rehabilitation in Parkinson’s disease alters the biochemical composition of circulating extracellular vesicle-like particles, particularly increasing carotenoid content, which correlates with improved gait paramete
This international trial demonstrates that personalized adaptive deep brain stimulation (aDBS) is a safe, effective, and well-tolerated long-term therapy for Parkinson’s disease patients previously stable on continuous DBS.
A large cohort study reveals that metabolic syndrome significantly raises Parkinson’s disease risk by 39%, with even greater risk in genetically predisposed individuals, highlighting the importance of metabolic health management in PD preve
A longitudinal study reveals that α-synuclein seed amplification assay kinetic measures enhance diagnostic accuracy and predict cognitive decline in Parkinson’s disease, independent of Alzheimer’s co-pathology.
